Palisade Bio Inc Financials

PALI

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Palisade Bio Inc (PALI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Palisade Bio Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.84x

For every $1 of reported earnings, Palisade Bio Inc generates $0.84 in operating cash flow (-$12.2M OCF vs -$14.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1238.3x

Palisade Bio Inc earns $-1238.3 in operating income for every $1 of interest expense (-$14.9M vs $12K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

YoY-100.0%

Palisade Bio Inc generated $0 in revenue in fiscal year 2024. This represents a decrease of 100.0% from the prior year.

EBITDA

-$14.9M

YoY-13.7%

Palisade Bio Inc's EBITDA was -$14.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.7% from the prior year.

Free Cash Flow

-$12.2M

YoY-9.5%

Palisade Bio Inc generated -$12.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 9.5% from the prior year.

Net Income

-$14.4M

YoY-17.4%

Palisade Bio Inc reported -$14.4M in net income in fiscal year 2024. This represents a decrease of 17.4% from the prior year.

EPS (Diluted)

$-10.19

Palisade Bio Inc earned $-10.19 per diluted share (EPS) in fiscal year 2024. This represents an increase of 62.3% from the prior year.

Cash & Debt

$9.8M

YoY-21.0%

5Y CAGR+13.9%

10Y CAGR-2.4%

Palisade Bio Inc held $9.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

Palisade Bio Inc had 3M shares outstanding in fiscal year 2024. This represents an increase of 348.0% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$9.1M

YoY+31.5%

5Y CAGR+17.4%

10Y CAGR+0.8%

Palisade Bio Inc invested $9.1M in research and development in fiscal year 2024. This represents an increase of 31.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Palisade Bio Inc invested $0 in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

PALI Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$0-100.0%	$250K	$0	N/A	$14K-12.2%	$15K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.1M+31.5%	$6.9M+5.3%	$6.5M+169.4%	$2.4M+20.4%	$2.0M-50.3%	$4.1M
SG&A Expenses	$5.8M-6.5%	$6.2M-29.2%	$8.8M-5.8%	$9.3M+50.2%	$6.2M+35.2%	$4.6M
Operating Income	-$14.9M-13.7%	-$13.1M+16.9%	-$15.7M+62.4%	-$41.9M-350.2%	-$9.3M-7.7%	-$8.6M
Interest Expense	$12K-20.0%	$15K+15.4%	$13K-99.5%	$2.4M+920.4%	$235K+2534.5%	$9K
Income Tax	$0	$0	$0	$0-100.0%	$1K	N/A
Net Income	-$14.4M-17.4%	-$12.3M+13.7%	-$14.3M+46.4%	-$26.6M-157.9%	-$10.3M-23.6%	-$8.4M
EPS (Diluted)	$-10.19	$-27.01	$-16.53	$-169.74	$-3.72	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$0	$0	$0	$0	$0	$0	N/A	$300K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.4M-16.8%	$1.7M+76.3%	$950K+108.1%	-$11.8M-548.2%	$2.6M+18.7%	$2.2M+511.6%	$362K-82.8%	$2.1M
SG&A Expenses	$1.5M+30.8%	$1.2M-14.1%	$1.4M+4.8%	$1.3M-18.0%	$1.6M+8.5%	$1.5M	N/A	$1.7M
Operating Income	-$2.9M-2.8%	-$2.8M-23.1%	-$2.3M+31.7%	-$3.4M+19.7%	-$4.2M-14.6%	-$3.7M	N/A	-$3.8M
Interest Expense	$5K+150.0%	$2K+100.0%	$1K-66.7%	$3K+50.0%	$2K+100.0%	$1K	N/A	$8K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.9M-3.0%	-$2.8M-24.8%	-$2.2M+33.3%	-$3.3M+18.0%	-$4.1M-15.7%	-$3.5M	N/A	-$3.6M
EPS (Diluted)	$-0.38	$-0.58-23.4%	$-0.47-1275.0%	$0.04+101.2%	$-3.32	$-4.59	N/A	$-7.38

PALI Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$10.9M-22.6%	$14.1M-10.9%	$15.8M+26.0%	$12.5M+314.4%	$3.0M-54.1%	$6.6M
Current Assets	$10.5M-21.3%	$13.3M-9.5%	$14.7M+28.0%	$11.5M+1184.2%	$896K-84.1%	$5.6M
Cash & Equivalents	$9.8M-21.0%	$12.4M+0.4%	$12.4M+18.0%	$10.5M+1371.9%	$713K-86.1%	$5.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$0	$0-100.0%	$59K+180.1%	$21K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.4M+23.7%	$2.7M-16.6%	$3.3M-36.2%	$5.1M-73.8%	$19.6M+31.5%	$14.9M
Current Liabilities	$3.2M+25.1%	$2.6M-14.1%	$3.0M+20.7%	$2.5M-69.1%	$8.1M+559.9%	$1.2M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$94K	N/A
Total Equity	$7.5M-33.8%	$11.3M-9.3%	$12.5M+69.4%	$7.4M+144.4%	-$16.6M-99.3%	-$8.3M
Retained Earnings	$135.9M+11.9%	$121.5M+11.3%	$109.2M+15.4%	$94.6M+239.1%	-$68.0M+69.4%	-$222.0M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$7.0M+4.6%	$6.7M-18.6%	$8.2M-24.7%	$10.9M-15.5%	$12.9M+1.7%	$12.7M-10.0%	$14.1M-17.7%	$17.1M
Current Assets	$6.8M+5.9%	$6.4M-18.3%	$7.9M-24.8%	$10.5M-14.8%	$12.3M+2.5%	$12.0M-9.9%	$13.3M-18.1%	$16.3M
Cash & Equivalents	$5.2M-3.5%	$5.4M-25.1%	$7.2M-26.4%	$9.8M-13.5%	$11.4M+0.7%	$11.3M-9.3%	$12.4M-18.8%	$15.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.8M-7.1%	$4.0M+41.6%	$2.9M-15.6%	$3.4M+15.9%	$2.9M+12.9%	$2.6M-5.5%	$2.7M-8.2%	$3.0M
Current Liabilities	$3.5M-12.4%	$4.0M+43.0%	$2.8M-14.2%	$3.2M+14.1%	$2.8M+15.0%	$2.5M-4.6%	$2.6M-2.4%	$2.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.2M+22.6%	$2.6M-50.9%	$5.3M-28.8%	$7.5M-24.7%	$9.9M-1.1%	$10.1M-11.0%	$11.3M-19.7%	$14.1M
Retained Earnings	N/A	$141.0M+2.0%	$138.2M+1.7%	$135.9M+205.3%	-$129.1M-3.3%	-$125.0M-202.9%	$121.5M+2.5%	$118.5M

PALI Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$12.2M-9.5%	-$11.1M+16.7%	-$13.4M+9.6%	-$14.8M-209.8%	-$4.8M+34.3%	-$7.3M
Capital Expenditures	$0-100.0%	$4K-60.0%	$10K	$0-100.0%	$6K	N/A
Free Cash Flow	-$12.2M-9.5%	-$11.1M+16.7%	-$13.4M+9.5%	-$14.8M-209.4%	-$4.8M	N/A
Investing Cash Flow	$0+100.0%	-$4K+60.0%	-$10K+81.5%	-$54K-800.0%	-$6K	N/A
Financing Cash Flow	$9.6M-14.3%	$11.2M-26.7%	$15.3M-38.0%	$24.6M+1202.1%	$1.9M-71.3%	$6.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$3.6M-95.5%	-$1.8M+22.1%	-$2.3M+2.0%	-$2.4M+32.0%	-$3.5M-10.0%	-$3.2M-15.8%	-$2.7M-3.2%	-$2.7M
Capital Expenditures	N/A	N/A	N/A	$0	N/A	N/A	$0	$0
Free Cash Flow	N/A	N/A	N/A	-$2.4M	N/A	N/A	-$2.7M-3.2%	-$2.7M
Investing Cash Flow	N/A	N/A	N/A	$0	N/A	N/A	$0	$0
Financing Cash Flow	$3.4M+83975.0%	$4K+101.6%	-$258K-106.2%	$4.2M+16.4%	$3.6M+76.7%	$2.0M+1610.4%	-$134K-108.5%	$1.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PALI Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-5228.0%	N/A	N/A	-68764.8%-12693.0pp	-56071.8%
Net Margin	N/A	-4920.0%	N/A	N/A	-76346.1%-22093.5pp	-54252.6%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-132.7%-45.2pp	-87.5%+2.9pp	-90.5%+122.3pp	-212.7%+129.2pp	-341.9%-215.1pp	-126.8%
Current Ratio	3.24-1.9	5.15+0.3	4.89+0.3	4.61+4.5	0.11-4.5	4.61
Debt-to-Equity	0.45+0.2	0.24-0.0	0.26+0.3	0.000.0	-0.01+1.8	-1.79
FCF Margin	N/A	-4454.8%	N/A	N/A	-35310.7%	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-1259.3%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-1198.7%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-41.1%+0.6pp	-41.8%-14.5pp	-27.2%+3.5pp	-30.7%+1.0pp	-31.7%-3.8pp	-27.9%	N/A	-21.1%
Current Ratio	1.96+0.3	1.62-1.2	2.84-0.4	3.24-1.1	4.34-0.5	4.87-0.3	5.15-1.0	6.14
Debt-to-Equity	1.17-0.4	1.54+1.0	0.54+0.1	0.45+0.2	0.29+0.0	0.26+0.0	0.24+0.0	0.21
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-887.3%

Similar Companies

GRI Bio GRI

$3.3M

60 degrees pharmaceuticals, Inc. SXTP

$4.1M

Titan Pharmaceut TTNP

$6.1M

Aditxt Inc ADTX

$1.1M

Frequently Asked Questions

What is Palisade Bio Inc's annual revenue?

Palisade Bio Inc (PALI) reported $0 in total revenue for fiscal year 2024. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Palisade Bio Inc's revenue growing?

Palisade Bio Inc (PALI) revenue declined by 100% year-over-year, from $250K to $0 in fiscal year 2024.

Is Palisade Bio Inc profitable?

No, Palisade Bio Inc (PALI) reported a net income of -$14.4M in fiscal year 2024.

What is Palisade Bio Inc's earnings per share (EPS)?

Palisade Bio Inc (PALI) reported diluted earnings per share of $-10.19 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Palisade Bio Inc's EBITDA?

Palisade Bio Inc (PALI) had EBITDA of -$14.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Palisade Bio Inc's free cash flow?

Palisade Bio Inc (PALI) generated -$12.2M in free cash flow during fiscal year 2024. This represents a -9.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Palisade Bio Inc's operating cash flow?

Palisade Bio Inc (PALI) generated -$12.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Palisade Bio Inc's total assets?

Palisade Bio Inc (PALI) had $10.9M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Palisade Bio Inc's capital expenditures?

Palisade Bio Inc (PALI) invested $0 in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Palisade Bio Inc spend on research and development?

Palisade Bio Inc (PALI) invested $9.1M in research and development during fiscal year 2024.

How many shares does Palisade Bio Inc have outstanding?

Palisade Bio Inc (PALI) had 3M shares outstanding as of fiscal year 2024.

What is Palisade Bio Inc's current ratio?

Palisade Bio Inc (PALI) had a current ratio of 3.24 as of fiscal year 2024, which is generally considered healthy.

What is Palisade Bio Inc's debt-to-equity ratio?

Palisade Bio Inc (PALI) had a debt-to-equity ratio of 0.45 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Palisade Bio Inc's return on assets (ROA)?

Palisade Bio Inc (PALI) had a return on assets of -132.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Palisade Bio Inc's cash runway?

Based on fiscal year 2024 data, Palisade Bio Inc (PALI) had $9.8M in cash against an annual operating cash burn of $12.2M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Palisade Bio Inc's Piotroski F-Score?

Palisade Bio Inc (PALI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Palisade Bio Inc's earnings high quality?

Palisade Bio Inc (PALI) has an earnings quality ratio of 0.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Palisade Bio Inc cover its interest payments?

Palisade Bio Inc (PALI) has an interest coverage ratio of -1238.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.